A biotechnology company developing stem cell therapies to treat neurodegenerative diseases
Our proprietary technology converts mesenchymal stem cells into NurOwn®, a biological drug delivery system designed to support damaged neurons
NurOwn® cells dampen the immune system and secrete growth factors that help damaged neurons survive.
BrainStorm Cell Therapeutics (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).
August 14, 2017BrainStorm Announces Second Quarter 2017 Financial Results
August 10, 2017Brainstorm to Host Second-Quarter 2017 Earnings Teleconference and Provide Important Corporate Updates, on Wednesday, August 16
August 7, 2017BrainStorm Supports Commitment to ALS Patient Community with Appointment of a Vice President of Patient Advocacy and Government Affairs
On July 17th, the Northeast ALS Consortium (NEALS) hosted a research webinar on the NurOwn® Clinical Development Program: Promising Phase 2 Results, Phase 3 Study Overview, and Hospital Exemption Program Update. They were joined by Robert Brown, MD, DPhil, University of Massachusetts, Merit Cudkowicz, MD, MSc, Massachusetts General Hospital, Anthony Windebank, MD, Mayo Clinic, Ralph Kern, MD, MHSc, BrainStorm Cell Therapeutics and Chaim Lebovits, BrainStorm Cell Therapeutics.